Lowest Price Guaranteed From USD 5,899
Published
January 2023
Slides
138
View Count
2333
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
Monkeypox is a viral disease, which is usually transmitted to humans from animals. The disease is known to have symptoms similar to those observed in smallpox patients, although it is considered to be clinically less severe. Monkeypox has recently emerged as a prominent orthopox virus affecting public health. In May 2022, multiple cases of the disease were reported in several non-endemic countries, thereby making monkeypox a disease of global concern. Consequently, in July 2022, the World Health Organization (WHO) declared global monkeypox outbreak a Public Health Emergency of International Concern (PHEIC). In fact, till date, over 71,000 cases of the disease have been reported, globally. In response to the monkeypox outbreak, active research and development efforts are underway to develop various therapeutics and vaccines for the treatment and prevention of monkeypox. Presently, more than 25 therapeutics / vaccines are commercialized / under development for the treatment and prevention of monkeypox. With the increase in the number of monkeypox cases globally, the demand for testing has also increased.
The Monkeypox Treatment Market - Distribution by Type of Product (Therapeutics and Vaccines), Drug Developers, Drug Candidates, Type of Diagnostic Kit (PCR Kits, Antigen Detection Kits and Antibody Detection Kits), Type of End User (Hospitals and Clinics, Diagnostic Laboratories and Other End Users) and Key Geographical Regions ( North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest Of Europe) and Asia-Pacific (Japan, Australia)): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players focused on the development of monkeypox therapeutics, vaccines and diagnostic kits. The report answers many key questions related to this domain.
Due to the surge in monkeypox cases in 2022, globally, there is a growing demand for monkeypox vaccines, therapeutics and diagnostic kits. With only a few therapeutics / vaccines currently approved or granted special access for the treatment / prevention of the monkeypox disease, the existing demand for effective monkeypox vaccines and therapeutics is still unmet. Additionally, the approved monkeypox vaccines are available at a high price, making it inaccessible to general population in developing countries, where the disease is endemic. In order to contain an outbreak, point-of-care diagnostics is very critical to ensure timely isolation and enable contact tracing of infected individuals. Therefore, considering the demand for diagnostic solutions for monkeypox virus, and the associated financial opportunity, both large companies and start-ups are competing to gain a foothold in this market.
The current monkeypox therapeutics and vaccines landscape is fragmented, featuring a mix of several large, mid-sized and small companies, which are engaged in the development of a number of therapy and vaccine candidates against the monkeypox virus. It is worth mentioning that, till date, only six therapeutics / vaccines, including ACAM2000®, IMVANEX® / JYNNEOS® / IMVAMUNE® and Cidofovir / Vistide, have either received approval or been granted special access for the treatment / prevention of the monkeypox virus infection. Additionally, more than 20 monkeypox therapeutics and vaccines are in the development pipeline. Post the 2022 outbreak of the monkeypox disease globally, interest in this area of research has grown significantly.
At present, more than 165 diagnostic kits are available in the market for the detection of monkeypox virus. It is worth highlighting that over 75% of the monkeypox diagnostic kits use polymerase chain reaction (PCR) as the detection technique, followed by antigen detection kits and antibody detection kits. In pursuit of gaining a competitive edge, monkeypox diagnostic kit providers are presently undertaking various initiatives in order to expand their existing capabilities and augment their respective product portfolios.
More than 70 countries across the world reported cases of monkeypox, with the maximum cases being reported in non-endemic regions. This outbreak has posed the risk of monkeypox virus spreading beyond endemic areas. Consequently, governments have undertaken several initiatives to increase awareness about monkeypox disease. Big pharma players are carrying out initiatives to strengthen their respective product portfolios focused on monkeypox disease. The growing cases of monkeypox disease and availability of limited number of therapeutics / vaccines / diagnostic solutions are the key factors driving the growth of this market.
Due to the increase in incidence of monkeypox infections and the growing demand for monkeypox vaccines and therapeutics, the monkeypox market is anticipated to witness a steady growth in the foreseen future. Presently, close to 80% of the monkeypox therapeutics and vaccines market is captured by players based in North America and Asia-Pacific.
The market for monkeypox diagnostic kits is anticipated to increase steadily in the foreseeable future due to the growing cases of the disease and the possibility of future outbreaks. Currently, over 60% of the diagnostic kits market is captured by players based in Asia-Pacific.
Examples of key players engaged in the monkeypox therapeutics and vaccines domain include (which have also been captured in this report) Bavarian Nordic and Emergent BioSolutions. Further, key players engaged in the monkeypox diagnostic kits domain include (which have also been captured in this report) ACON Laboratories, altona Diagnostics, Jiangsu Bioperfectus Technologies, Elabscience, Goldsite Diagnostics, Lansion Biotechnology, DNA Software and Hangzhou Testsea Biotechnology.
Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
Report Attribute | Details | |
Forecast Period |
2023 – 2035 |
|
Type of Product |
Therapeutics, Vaccines | |
Drug Developers |
Company 1, Company 2, Company 3, Company 4 and Company 5 | |
Drug Candidates |
Drug Candidate 1, Drug Candidate 2, Drug Candidate 3, Drug Candidate 4, Drug Candidate 5, Drug Candidate 6 and Drug Candidate 7 | |
Types of Kits |
PCR Kits, Antigen Detection Kits and Antibody Detection Kits |
|
Type of End Users |
Hospitals and Clinics, Diagnotic Laboratories and Other End Users | |
Key Geographical Regions | North America (US and Canada), Europe (UK, France, Germany, Spain, Italy, Rest of EU) and Asia-Pacific (Japan and Australia) | |
Key Companies Profiled | Software, Elabscience, Goldsite Diagnostics, Hangzhou Testsea Biotechnology, Jiangsu Bioperfectus Technologies, Lansion Biotechnology, Bavarian Nordic and Emergent BioSolutions | |
Customization Scope | 15% Free Customization Option (equivalent to 5 analyst working days) | |
PowerPoint Presentation (Complimentary) | Available | |
Excel Data Packs (Complimentary) | Market Landscape Analysis, Product Competitiveness Analysis, Partnership and Collaboration Analysis, Grant Analysis, Publication Analysis, Porter's Five Forces Analysis, Market Forecast an Opportunity Analysis |
Amongst other elements, the report also includes:
One of the key objectives of this report was to estimate the existing market opportunity and the future growth potential of the monkeypox therapeutics / vaccines and diagnostic kits over the coming years. Based on multiple parameters, such as incidences of monkeypox, target population to be vaccinated / treated, cost of therapeutics / vaccines, we have provided an informed estimate on the evolution of the monkeypox therapeutics / vaccines market for the period 2023-2035. Similarly, we have estimated the monkeypox diagnostic kits market for the period 2023-2035 based on multiple parameters, such as incidences of monkeypox, testing population across the world, popularity of type of kits available and cost of kits. The report features the likely distribution of the current and forecasted opportunity across various types of products (therapeutics and vaccines), drug developers, drug candidates and key geographical regions (North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest of Europe) and Asia-Pacific (Japan, Australia)) for monkeypox therapeutics / vaccines market. For monkeypox diagnostic kits market, the report features likely distribution of the current and forecasted opportunity across various types of kits (PCR Kits, Antigen Detection Kits and Antibody Detection Kits), type of end users (Hospitals and Clinics, Diagnostic Laboratories and Other End Users) and key geographical regions (North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest of Europe) and Asia-Pacific (Japan, Australia))
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
Question 1: What are the first signs of monkeypox?
Answer: The first signs and symptoms of monkeypox include high temperature, headache, muscle ache, backache, swollen glands, chills, joint pain and exhaustion.
Question 2: What is the growth rate of monkeypox therapeutics and vaccines market?
Answer: Monkeypox therapeutics / vaccines market is anticipated to witness a decline over the next decade; this is likely to be the result of a dip in the number of monkeypox cases till 2035.
Question 3: What is the growth rate of monkeypox diagnostic kits market?
Answer: Monkeypox diagnostic kits market is expected to witness a decline over the next decade due to the dip in the number of monkeypox cases till 2035.
Question 4: Who are the key developers of monkeypox therapeutics / vaccines?
Answer: Examples of key players currently developing monkeypox therapeutics / vaccines include Bavarian Nordic, Emergent BioSolutions and KM Biologics and SIGA Technologies.
Question 5: Who are the key developers of monkeypox diagnostic kits?
Answer: Examples of key players currently developing monkeypox diagnostic kits include ACON Laboratories, altona Diagnostics, DNA Software, Elabscience, Goldsite Diagnostics, Hangzhou Testsea Biotechnology, Jiangsu Bioperfectus Technologies and Lansion Biotechnology.
Question 6: How many players are offering monkeypox therapeutics / vaccines and diagnostic kits?
Answer: Currently, more than 20 players are developing monkeypox therapeutics / vaccines. Additionally, over 120 players are involved in the development of diagnostic kits for monkeypox.
Question 7: What is the count of monkeypox diagnostic kits available in the market?
Answer: At present, more than 150 monkeypox diagnostic kits are available in the market. Moreover, close to 10 kits are currently under development for diagnosis of monkeypox.
Question 8: How many therapeutics and vaccines are approved for the treatment and prevention of monkeypox?
Answer: Presently, six therapeutics / vaccines have been approved or granted special access for the treatment / prevention of monkeypox.
Question 9: Which type of diagnostic kit accounts for the largest monkeypox market share?
Answer: In the current market, polymerase chain reaction (PCR) based detection kits for monkeypox represent the largest market share.
Question 10: Which segment, in terms of type of product, accounts for the largest monkeypox therapeutics / vaccines market share?
Answer: At present, vaccines account for the largest market share, in terms of revenues, in the global monkeypox therapeutics / vaccines market.
Contents
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. An Overview of Monkeypox
2.2. Signs and Symptoms
2.3. History of Disease Outbreaks
2.4. Disease Transmission
2.5. Disease Diagnosis
2.6. Prevention and Treatment
2.6.1 Prevention Measures
2.6.2 Available Therapeutics and Vaccines
2.7. Future Perspectives
3. MARKET LANDSCAPE: MONKEYPOX THERAPEUTICS AND VACCINES
3.1. Monkeypox Therapeutics and Vaccines: Overall Market Landscape
3.1.1 Analysis by Phase of Development
3.1.2 Analysis by Type of Product
3.1.3 Analysis by Phase of Development and Type of Product
3.1.4 Analysis by Type of Molecule
3.1.5 Analysis by Type of Dosage Form
3.1.6 Analysis by Route of Administration
3.2. Monkeypox Therapeutics and Vaccines: Developer Landscape
3.2.1 Analysis by Year of Establishment
3.2.2 Analysis by Type of Player
3.2.3 Analysis by Geography (Region-wise)
3.2.4 Analysis by Company Size and Geography (Region-wise)
3.2.5 Leading Developers: Analysis by Number of Therapeutics / Vaccines
4. MARKET LANDSCAPE: MONKEYPOX DIAGNOSTIC KITS
4.1. Monkeypox Diagnostic Kits: Overall Market Landscape
4.1.1. Analysis by Type of Sample
4.1.2. Analysis by Type of Kit Component
4.1.3. Analysis by Clade of Virus Detected
4.1.4. Analysis by Detection Method
4.1.5. Analysis by Application Area
4.1.6. Analysis by Type of Kit
4.1.7. Analysis by Quantity of Sample
4.1.8. Analysis by Turnaround Time
4.1.9 Analysis by Limit of Detection
4.1.10. Analysis by Number of Tests per Kit
4.1.11 Analysis by Shelf Life
4.1.12 Analysis by Storage Temperature
4.2 Monkeypox Diagnostic Kits: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Developer
4.2.6. Key Developers: Analysis by Number of Diagnostic Kits Developed
5. MONKEYPOX DIAGNOSTIC KITS: PRODUCT COMPETITIVENESS ANALYSIS
5.1. Methodology
5.2. Product Competitiveness Analysis: Monkeypox Diagnostic Kits
6. COMPANY PROFILES: MONKEYPOX THERAPEUTICS AND VACCINES DEVELOPERS
6.1. Bavarian Nordic
6.1.1. Company Overview
6.1.2. Monkeypox Therapeutics / Vaccines Portfolio
6.1.3. Recent Developments and Future Outlook
6.2. Emergent BioSolutions
6.2.1. Company Overview
6.2.2. Monkeypox Therapeutics / Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
7. COMPANY PROFILES: MONKEYPOX DIAGNOSTIC KITS DEVELOPERS
7.1. ACON Laboratories
7.1.1. Company Overview
7.1.2. Monkeypox Diagnostic Kits Portfolio
7.2. altona Diagnostics
7.2.1. Company Overview
7.2.2. Monkeypox Diagnostic Kits Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DNA Software
7.3.1. Company Overview
7.3.2. Monkeypox Diagnostic Kits Portfolio
7.4. Elabscience
7.4.1. Company Overview
7.4.2. Monkeypox Diagnostic Kits Portfolio
7.5. Goldsite Diagnostics
7.5.1. Company Overview
7.5.2. Monkeypox Diagnostic Kits Portfolio
7.6. Hangzhou Testsea Biotechnology
7.6.1. Company Overview
7.6.2. Monkeypox Diagnostic Kits Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Jiangsu Bioperfectus Technologies
7.7.1. Company Overview
7.7.2. Monkeypox Diagnostic Kits Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. Lansion Biotechnology
7.8.1. Company Overview
7.8.2. Monkeypox Diagnostic Kits Portfolio
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Partnerships and Collaborations
8.1.1. Analysis by Year of Partnership
8.1.2. Analysis by Type of Partnership
8.1.3. Analysis by Year and Type of Partnership
8.1.4. Analysis by Focus Area
8.1.5. Analysis by Type of Partner
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Local and International Agreements
8.1.8. Analysis by Intercontinental and Intracontinental Agreements
9. GRANTS ANALYSIS
9.1. Scope and Methodology
9.2. Key Parameters
9.3. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Grants Analysis
9.3.1. Analysis by Year of Grant Awarded
9.3.2. Analysis by Support Period
9.3.3. Analysis by Amount Awarded
9.3.4. Analysis by Leading Funding Institute Centre
9.3.5. Analysis by Type of Grant
9.3.6. Analysis by Activity Code
9.3.7. Analysis by Study Section Involved
9.3.8. Analysis by Purpose of Grant
9.3.9. Prominent Program Officers: Analysis by Number of Grants
9.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
9.3.11. Most Popular Departments: Analysis by Number of Grants
9.3.12. Analysis by Location of Recipient
10. PUBLICATION ANALYSIS
10.1. Methodology and Parameters
10.2. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Publication Analysis
10.2.1. Analysis by Year of Publication
10.2.2. Analysis by Type of Publication
10.2.3. Most Popular Journals: Analysis by Number of Publications
10.2.4. Most Popular Journals: Analysis by Journal Impact Factor
10.2.5. Popular Keywords: Analysis by Key Focus Areas
10.2.6. Most Active Publishers: Analysis by Number of Publications
10.2.7. Most Popular Affiliations: Analysis by Number of Publications
10.2.8. Analysis by Geography
11. PORTER’S FIVE FORCES ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Porter’s Five Forces
11.3.1. Threat of New Entrants
11.3.2. Bargaining Power of End Users
11.3.3. Bargaining Power of Drug Developers
11.3.4. Threat of Substitute Products
11.3.5. Rivalry Among Existing Competitors
12. MARKET FORECAST: MONKEYPOX THERAPEUTICS AND VACCINES
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Monkeypox Therapeutics and Vaccines Market, 2023-2035
12.3.1. Monkeypox Therapeutics and Vaccines Market: Analysis by Type of Product, 2023 and 2035
12.3.1.1. Monkeypox Therapeutics Market, 2023-2035
12.3.1.2. Monkeypox Vaccines Market, 2023-2035
12.3.2. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Developers, 2023 and 2035
12.3.2.1. Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035
12.3.2.2. Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035
12.3.2.3. Monkeypox Therapeutics and Vaccines Market for KM Biologics, 2023-2035
12.3.2.4. Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035
12.3.3. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Candidates, 2023 and 2035
12.3.3.1. IMVANEX® / JYNNEOS® / IMVAMUNE® (Bavarian Nordic): Sales Forecast, 2023-2035
12.3.3.2. ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.3. LC16KMB (KM Biologics): Sales Forecast, 2023-2035
12.3.3.4. Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035
12.3.3.5. VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.4. Monkeypox Therapeutics and Vaccines Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Monkeypox Therapeutics and Vaccines Market in North America, 2023-2035
12.3.4.1.1. Monkeypox Therapeutics and Vaccines Market in the US, 2023-2035
12.3.4.1.2. Monkeypox Therapeutics and Vaccines Market in Canada, 2023-2035
12.3.4.2. Monkeypox Therapeutics and Vaccines Market in Europe, 2023-2035
12.3.4.2.1. Monkeypox Therapeutics and Vaccines Market in the UK, 2023-2035
12.3.4.2.2. Monkeypox Therapeutics and Vaccines Market in Germany, 2023-2035
12.3.4.2.3. Monkeypox Therapeutics and Vaccines Market in Spain, 2023-2035
12.3.4.2.4. Monkeypox Therapeutics and Vaccines Market in France, 2023-2035
12.3.4.2.5. Monkeypox Therapeutics and Vaccines Market in Italy, 2023-2035
12.3.4.2.6. Monkeypox Therapeutics and Vaccines Market in Rest of Europe, 2023-2035
12.3.4.3. Monkeypox Therapeutics and Vaccines Market in Asia Pacific, 2023-2035
12.3.4.3.1. Monkeypox Therapeutics and Vaccines Market in Japan, 2023-2035
12.3.4.3.2. Monkeypox Therapeutics and Vaccines Market in Australia, 2023-2035
13. MARKET FORECAST: MONKEYPOX DIAGNOSTIC KITS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Monkeypox Diagnostic Kits Market, 2023-2028
13.3.1. Monkeypox Diagnostic Kits Market: Analysis by Type of Kit, 2023 and 2028
13.3.1.1. Monkeypox Polymerase Chain Reaction (PCR) Detection Kits Market, 2023-2028
13.3.1.2. Monkeypox Antigen Detection Kits Market, 2023-2028
13.3.1.3 Monkeypox Antibody Detection Kits Market, 2023-2028
13.3.2. Monkeypox Diagnostic Kits Market: Analysis by Type of End User, 2023 and 2028
13.3.2.1. Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2028
13.3.2.2. Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2028
13.3.2.3. Monkeypox Diagnostic Kits Market for Other End Users, 2023-2028
13.3.3. Monkeypox Diagnostic Kits Market: Analysis by Geography, 2023 and 2028
13.3.3.1. Monkeypox Diagnostic Kits Market in North America, 2023-2028
13.3.3.1.1. Monkeypox Diagnostic Kits Market in the US, 2023-2028
13.3.3.1.2. Monkeypox Diagnostic Kits Market in Canada, 2023-2028
13.3.3.2. Monkeypox Diagnostic Kits Market in Europe, 2023-2028
13.3.3.2.1. Monkeypox Diagnostic Kits Market in the UK, 2023-2028
13.3.3.2.2. Monkeypox Diagnostic Kits in France, 2023-2028
13.3.3.2.3. Monkeypox Diagnostic Kits Market in Germany, 2023-2028
13.3.3.2.4. Monkeypox Diagnostic Kits Market in Spain, 2023-2028
13.3.3.2.5. Monkeypox Diagnostic Kits Market in Italy, 2023-2028
13.3.3.2.6. Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2028
13.3.3.3. Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2028
14. EXECUTIVE INSIGHTS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 1.1 Executive Summary: Overall Market Landscape of Monkeypox Therapeutics and Vaccines
Figure 1.2 Executive Summary: Overall Market Landscape of Monkeypox Diagnostic Kits
Figure 1.3 Executive Summary: Partnerships and Collaborations
Figure 1.4 Executive Summary: Grant Analysis
Figure 1.5 Executive Summary: Publication Analysis
Figure 1.6 Executive Summary: Market Forecast and Opportunity Analysis of Monkeypox Therapeutics and Vaccines
Figure 1.7 Executive Summary: Market Forecast and Opportunity Analysis of Monkeypox Diagnostic Kits
Figure 3.1 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development
Figure 3.2 Monkeypox Therapeutics / Vaccines: Distribution by Type of Product
Figure 3.3 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development and Type of Product
Figure 3.4 Monkeypox Therapeutics / Vaccines: Distribution by Type of Molecule
Figure 3.5 Monkeypox Therapeutics / Vaccines: Distribution by Type of Dosage Form
Figure 3.6 Monkeypox Therapeutics / Vaccines: Distribution by Route of Administration
Figure 3.7 Monkeypox Therapeutics / Vaccines Developers: Distribution by Year of Establishment
Figure 3.8 Monkeypox Therapeutics / Vaccines Developers: Distribution by Type of Player
Figure 3.9 Monkeypox Therapeutics / Vaccines Developers: Distribution by Geography (Region-wise)
Figure 3.10 Monkeypox Therapeutics / Vaccines Developers: Distribution by Company Size and Geography (Region-wise)
Figure 3.11 Leading Developers: Distribution by Number of Therapeutics / Vaccines
Figure 4.1 Monkeypox Diagnostic Kits: Distribution by Type of Sample
Figure 4.2 Monkeypox Diagnostic Kits: Distribution by Type of Kit Component
Figure 4.3 Monkeypox Diagnostic Kits: Distribution by Clade of Virus Detected
Figure 4.4 Monkeypox Diagnostic Kits: Distribution by Detection Method
Figure 4.5 Monkeypox Diagnostic Kits: Distribution by Application Area
Figure 4.6 Monkeypox Diagnostic Kits: Distribution by Type of Kit
Figure 4.7 Monkeypox Diagnostic Kits: Distribution by Quantity of Sample
Figure 4.8 Monkeypox Diagnostic Kits: Distribution by Turnaround Time
Figure 4.9 Monkeypox Diagnostic Kits: Distribution by Limit of Detection
Figure 4.10 Monkeypox Diagnostic Kits: Distribution by Number of Tests per Kit
Figure 4.11 Monkeypox Diagnostic Kits: Distribution by Shelf Life
Figure 4.12 Monkeypox Diagnostic Kits: Distribution by Storage Temperature
Figure 4.13 Monkeypox Diagnostic Kits Developers: Distribution by Year of Establishment
Figure 4.14 Monkeypox Diagnostic Kits Developers: Distribution by Company Size
Figure 4.15 Monkeypox Diagnostic Kits Developers: Distribution by Location of Headquarters
Figure 4.16 Monkeypox Diagnostic Kits Developers: Distribution by Company Size and Location of Headquarters
Figure 4.17 Monkeypox Diagnostic Kits Developers: Distribution by Type of Developer
Figure 4.18 Leading Developers: Distribution by Number of Diagnostic Kits
Figure 5.1 Product Competitiveness Analysis: Dot-Plot Representation of Monkeypox Diagnostic Kits
Figure 5.2 Product Competitiveness Analysis: Top Monkeypox Diagnostic Kits
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2018-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Local and International Agreements
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Grants Analysis: Distribution by Year of Grant Awarded
Figure 9.2 Grants Analysis: Distribution by Support Period
Figure 9.3 Grants Analysis: Distribution by Amount Awarded
Figure 9.4 Grants Analysis: Distribution by Leading Funding Institute Centre
Figure 9.5 Grants Analysis: Distribution by Type of Grant
Figure 9.6 Grants Analysis: Distribution by Activity Code
Figure 9.7 Grants Analysis: Distribution by Study Section Involved
Figure 9.8 Grants Analysis: Distribution by Purpose of Grant
Figure 9.9 Grants Analysis: Prominent Program Officers
Figure 9.10 Grants Analysis: Popular Recipient Organizations
Figure 9.11 Grants Analysis: Distribution by Popular NIH Departments
Figure 9.12 Grants Analysis: Distribution by Location of Recipient
Figure 10.1 Publication Analysis: Distribution by Year of Publication
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Most Popular Journals: Distribution by Number of Publications
Figure 10.4 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.5 Most Popular Keywords: Distribution by Key Focus Areas
Figure 10.6 Most Active Publishers: Distribution by Number of Publications
Figure 10.7 Most Popular Affiliations: Distribution by Number of Publications
Figure 10.8 Publication Analysis: Distribution by Geography
Figure 11.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Porter’s Five Forces Analysis
Figure 12.1 Global Monkeypox Therapeutics and Vaccines Market, 2023-2035 (USD Million)
Figure 12.2 Monkeypox Therapeutics and Vaccines Market: Distribution by Type of Product, 2023 and 2035 (USD Million)
Figure 12.3 Monkeypox Therapeutics Market, 2023-2035 (USD Million)
Figure 12.4 Monkeypox Vaccines Market, 2023-2035 (USD Million)
Figure 12.5 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Developers, 2023 and 2035 (USD Million)
Figure 12.6 Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035 (USD Million)
Figure 12.7 Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035 (USD Million)
Figure 12.8 Monkeypox Therapeutics and Vaccines Market for KM Biologics, 2023-2035 (USD Million)
Figure 12.9 Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035 (USD Million)
Figure 12.10 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Candidates, 2023 and 2035 (USD Million)
Figure 12.11 IMVANEX® / JYNNEOS® / IMVAMUNER® (Bavarian Nordic): Sales Forecast, 2023-2035 (USD Million)
Figure 12.12 ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035 (USD Million)
Figure 12.13 LC16KMB (KM Biologics): Sales Forecast, 2023-2035 (USD Million)
Figure 12.14 Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035 (USD Million)
Figure 12.15 VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035 (USD Million)
Figure 12.16 Monkeypox Therapeutics and Vaccines Market: Distribution by Geography, 2023 and 2035 (USD Million)
Figure 12.17 Monkeypox Therapeutics and Vaccines Market in North America, 2023-2035 (USD Million)
Figure 12.18 Monkeypox Therapeutics and Vaccines Market in the US, 2023-2035 (USD Million)
Figure 12.19 Monkeypox Therapeutics and Vaccines Market in Canada, 2023-2035 (USD Million)
Figure 12.20 Monkeypox Therapeutics and Vaccines Market in Europe, 2023-2035 (USD Million)
Figure 12.21 Monkeypox Therapeutics and Vaccines Market in the UK, 2023-2035 (USD Million)
Figure 12.22 Monkeypox Therapeutics and Vaccines Market in Germany, 2023-2035 (USD Million)
Figure 12.23 Monkeypox Therapeutics and Vaccines Market in Spain, 2023-2035 (USD Million)
Figure 12.24 Monkeypox Therapeutics and Vaccines Market in France, 2023-2035 (USD Million)
Figure 12.25 Monkeypox Therapeutics and Vaccines Market in Italy, 2023-2035 (USD Million)
Figure 12.26 Monkeypox Therapeutics and Vaccines Market in Rest of Europe, 2023-2035 (USD Million)
Figure 12.27 Monkeypox Therapeutics and Vaccines Market in Asia Pacific, 2023-2035 (USD Million)
Figure 12.28 Monkeypox Therapeutics and Vaccines Market in Japan, 2023-2035 (USD Million)
Figure 12.29 Monkeypox Therapeutics and Vaccines Market in Australia, 2023-2035 (USD Million)
Figure 13.1 Global Monkeypox Diagnostic Kits Market, 2023-2028 (USD Million)
Figure 13.2 Monkeypox Diagnostic Kits Market: Distribution by Type of Kit, 2023 and 2028 (USD Million)
Figure 13.3 Monkeypox Diagnostic Kits Market for Polymerase Chain Reaction (PCR) Detection Kits, 2023-2028 (USD Million)
Figure 13.4 Monkeypox Diagnostic Kits Market for Antigen Detection Kits, 2023-2028 (USD Million)
Figure 13.5 Monkeypox Diagnostic Kits Market for Antibody Detection Kits, 2023-2028 (USD Million)
Figure 13.6 Monkeypox Diagnostic Kits Market for Type of End User, 2023 and 2028 (USD Million)
Figure 13.7 Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2028 (USD Million)
Figure 13.8 Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2028 (USD Million)
Figure 13.9 Monkeypox Diagnostic Kits Market for Other End Users, 2023-2028 (USD Million)
Figure 13.10 Monkeypox Diagnostic Kits Market: Distribution by Geography, 2023 and 2028 (USD Million)
Figure 13.11 Monkeypox Diagnostic Kits Market in North America, 2023-2028 (USD Million)
Figure 13.12 Monkeypox Diagnostic Kits Market in the US, 2023-2028 (USD Million)
Figure 13.13 Monkeypox Diagnostic Kits Market in Canada, 2023-2028 (USD Million)
Figure 13.14 Monkeypox Diagnostic Kits Market in Europe, 2023-2028 (USD Million)
Figure 13.15 Monkeypox Diagnostic Kits Market in the UK, 2023-2028 (USD Million)
Figure 13.16 Monkeypox Diagnostic Kits Market in France, 2023-2028 (USD Million)
Figure 13.17 Monkeypox Diagnostic Kits Market in Germany, 2023-2028 (USD Million)
Figure 13.18 Monkeypox Diagnostic Kits Market in Spain, 2023-2028 (USD Million)
Figure 13.19 Monkeypox Diagnostic Kits Market in Italy, 2023-2028 (USD Million)
Figure 13.20 Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2028 (USD Million)
Figure 13.21 Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2028 (USD Million)
Figure 13.22 Monkeypox Diagnostic Kits Market in Rest of the World, 2023-2028 (USD Million)
Table 3.1 Monkeypox Market: List of Monkeypox Therapeutics / Vaccines
Table 3.2 Monkeypox Market: List of Monkeypox Therapeutics / Vaccines Developers
Table 4.1 Monkeypox Market: List of Monkeypox Diagnostic Kits
Table 4.2 Monkeypox Market: List of Monkeypox Diagnostic Kits Developers
Table 6.1 Bavarian Nordic: Monkeypox Therapeutics / Vaccines Portfolio
Table 6.2 Bavarian Nordic: Recent Developments and Future Outlook
Table 6.3 Emergent: Monkeypox Therapeutics / Vaccines Portfolio
Table 6.4 Emergent: Recent Developments and Future Outlook
Table 7.1 ACON Laboratories: Monkeypox Diagnostic Kits Portfolio
Table 7.2 altona Diagnostics: Monkeypox Diagnostic Kits Portfolio
Table 7.3 altona Diagnostics: Recent Developments and Future Outlook
Table 7.4 Bioperfectus Technologies: Monkeypox Diagnostic Kits Portfolio
Table 7.5 Bioperfectus Technologies: Recent Developments and Future Outlook
Table 7.6 DNA Software: Monkeypox Diagnostic Kits Portfolio
Table 7.7 Elabscience Biotechnology: Monkeypox Diagnostic Kits Portfolio
Table 7.8 Goldsite Diagnostics: Monkeypox Diagnostic Kits Portfolio
Table 7.9 Lansion Biotechnology: Monkeypox Diagnostic Kits Portfolio
Table 7.10 Testsealabs: Monkeypox Diagnostic Kits Portfolio
Table 7.11 Testsealabs: Recent Developments and Future Outlook
Table 8.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: List of Partnerships and Collaborations
Table 9.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: List of Grants
Table 10.1 Monkeypox Therapeutics / Vaccines and Diagnostic Kits: List of Publications
Table 15.1 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development
Table 15.2 Monkeypox Therapeutics / Vaccines: Distribution by Type of Product
Table 15.3 Monkeypox Therapeutics / Vaccines: Distribution by Phase of Development and Type of Product
Table 15.4 Monkeypox Therapeutics / Vaccines: Distribution by Type of Molecule
Table 15.5 Monkeypox Therapeutics / Vaccines: Distribution by Type of Dosage Form
Table 15.6 Monkeypox Therapeutics / Vaccines: Distribution by Route of Administration
Table 15.7 Monkeypox Therapeutics / Vaccines Developers: Distribution by Year of Establishment
Table 15.8 Monkeypox Therapeutics / Vaccines Developers: Distribution by Type of Player
Table 15.9 Monkeypox Therapeutics / Vaccines Developers: Distribution by Geography (Region-wise)
Table 15.10 Monkeypox Therapeutics / Vaccines Developers: Distribution by Company Size and Geography (Region-wise)
Table 15.11 Leading Developers: Distribution by Number of Therapeutics / Vaccines
Table 15.12 Monkeypox Diagnostic Kits: Distribution by Type of Sample
Table 15.13 Monkeypox Diagnostic Kits: Distribution by Type of Kit Component
Table 15.14 Monkeypox Diagnostic Kits: Distribution by Clade of Virus Detected
Table 15.15 Monkeypox Diagnostic Kits: Distribution by Detection Method
Table 15.16 Monkeypox Diagnostic Kits: Distribution by Application Area
Table 15.17 Monkeypox Diagnostic Kits: Distribution by Type of Kit
Table 15.18 Monkeypox Diagnostic Kits: Distribution by Quantity of Sample
Table 15.19 Monkeypox Diagnostic Kits: Distribution by Turnaround Time
Table 15.20 Monkeypox Diagnostic Kits: Distribution by Limit of Detection
Table 15.21 Monkeypox Diagnostic Kits: Distribution by Number of Tests per Kit
Table 15.22 Monkeypox Diagnostic Kits: Distribution by Shelf Life
Table 15.23 Monkeypox Diagnostic Kits: Distribution by Storage Temperature
Table 15.24 Monkeypox Diagnostic Kits Developers: Distribution by Year of Establishment
Table 15.25 Monkeypox Diagnostic Kits Developers: Distribution by Company Size
Table 15.26 Monkeypox Diagnostic Kits Developers: Distribution by Location of Headquarters
Table 15.27 Monkeypox Diagnostic Kits Developers: Distribution by Company Size and Location of Headquarters
Table 15.28 Monkeypox Diagnostic Kits Developers: Distribution by Type of Developer
Table 15.29 Leading Developers: Distribution by Number of Diagnostic Kits
Table 15.30 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2018-2022
Table 15.31 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.32 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 15.33 Partnerships and Collaborations: Distribution by Focus Area
Table 15.34 Partnerships and Collaborations: Distribution by Type of Partner
Table 15.35 Most Active Players: Distribution by Number of Partnerships
Table 15.36 Partnerships and Collaborations: Local and International Agreements
Table 15.37 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.38 Grants Analysis: Distribution by Year of Grant Awarded
Table 15.39 Grants Analysis: Distribution by Support Period
Table 15.40 Grants Analysis: Distribution by Amount Awarded
Table 15.41 Grants Analysis: Distribution by Leading Funding Institute Centre
Table 15.42 Grants Analysis: Distribution by Type of Grant
Table 15.43 Grants Analysis: Distribution by Activity Code
Table 15.44 Grants Analysis: Distribution by Study Section Involved
Table 15.45 Grants Analysis: Distribution by Purpose of Grant
Table 15.46 Grants Analysis: Prominent Program Officers
Table 15.47 Grants Analysis: Popular Recipient Organizations
Table 15.48 Grants Analysis: Distribution by Popular NIH Departments
Table 15.49 Grants Analysis: Distribution by Location of Recipient
Table 15.50 Publication Analysis: Distribution by Year of Publication
Table 15.51 Publication Analysis: Distribution by Type of Publication
Table 15.52 Most Popular Journals: Distribution by Number of Publications
Table 15.53 Most Popular Journals: Distribution by Journal Impact Factor
Table 15.54 Most Popular Keywords: Distribution by Key Focus Areas
Table 15.55 Most Active Publishers: Distribution by Number of Publications
Table 15.56 Most Popular Affiliations: Distribution by Number of Publications
Table 15.57 Publication Analysis: Distribution by Geography
Table 15.58 Global Monkeypox Therapeutics and Vaccines Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.59 Monkeypox Therapeutics and Vaccines Market: Distribution by Type of Product, 2023 and 2035 (USD Million)
Table 15.60 Monkeypox Therapeutics and Vaccines Market for Therapeutics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.61 Monkeypox Therapeutics and Vaccines Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.62 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Developers, 2023 and 2035 (USD Million)
Table 15.63 Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.64 Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.65 Monkeypox Therapeutics and Vaccines Market for KM Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.66 Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.67 Monkeypox Therapeutics and Vaccines Market: Distribution by Drug Candidates, 2023 and 2035 (USD Million)
Table 15.68 IMVANEX® / JYNNEOS® / IMVAMUNER® (Bavarian Nordic): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.69 ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035 Conservative, Base and Optimistic Scenarios, (USD Million)
Table 15.70 LC16KMB (KM Biologics): Sales Forecast, 2023-2035 Conservative, Base and Optimistic Scenarios, (USD Million)
Table 15.71 Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.72 VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.73 Monkeypox Therapeutics and Vaccines Market: Distribution by Geography, 2023 and 2035 (USD Million)
Table 15.74 Monkeypox Therapeutics and Vaccines Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.75 Monkeypox Therapeutics and Vaccines Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.76 Monkeypox Therapeutics and Vaccines Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.77 Monkeypox Therapeutics and Vaccines Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.78 Monkeypox Therapeutics and Vaccines Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.79 Monkeypox Therapeutics and Vaccines Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.80 Monkeypox Therapeutics and Vaccines Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.81 Monkeypox Therapeutics and Vaccines Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.82 Monkeypox Therapeutics and Vaccines Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.83 Monkeypox Therapeutics and Vaccines Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.84 Monkeypox Therapeutics and Vaccines Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.85 Monkeypox Therapeutics and Vaccines Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.86 Monkeypox Therapeutics and Vaccines Market in Australia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 15.87 Global Monkeypox Diagnostic Kits Market, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.88 Monkeypox Diagnostic Kits Market: Distribution by Type of Kit, 2023 and 2028 (USD Million)
Table 15.89 Monkeypox Diagnostic Kits Market for Polymerase Chain Reaction (PCR) Detection Kits, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.90 Monkeypox Diagnostic Kits Market for Antigen Detection Kits, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.91 Monkeypox Diagnostic Kits Market for Antibody Detection Kits, 2023 and 2028 (USD Million)
Table 15.92 Monkeypox Diagnostic Kits Market for Type of End User, 2023-2028 (USD Million)
Table 15.93 Monkeypox Diagnostic Kits Market for Hospitals and Clinics, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.94 Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.95 Monkeypox Diagnostic Kits Market for Other Users, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.96 Monkeypox Diagnostic Kits Market: Distribution by Geography, Conservative, Base and Optimistic Scenarios, 2023 and 2028 (USD Million)
Table 15.97 Monkeypox Diagnostic Kits Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.98 Monkeypox Diagnostic Kits Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.99 Monkeypox Diagnostic Kits Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.100 Monkeypox Diagnostic Kits Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.101 Monkeypox Diagnostic Kits Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.102 Monkeypox Diagnostic Kits Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.103 Monkeypox Diagnostic Kits Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.104 Monkeypox Diagnostic Kits Market in France, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.105 Monkeypox Diagnostic Kits Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.106 Monkeypox Diagnostic Kits Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.107 Monkeypox Diagnostic Kits Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
Table 15.108 Monkeypox Diagnostic Kits Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2028 (USD Million)
The following companies and organizations have been mentioned in the report:
Source 1: https://www.citizen.org/article/letter-to-bavarian-nordic-urging-equitable-access/
Source 2: https://jamanetwork.com/journals/jama/fullarticle/2794922#:~:text=On%20July%2023%2C%202022,9%20against%20recommending%20a%20PHEIC